Serina Therapeutics, Inc. (SER): Nasdaq/NYSE listing notice — AgeX receives NYSE American delisting notice for low stockholders' equity; faces potential delisting by May 17, 2023

Serina Therapeutics, Inc.

NYSE American cited AgeX for stockholders' equity below $2M, $4M, and $6M thresholds with sustained losses.
AgeX must comply or show progress by May 17, 2023, or delisting proceedings will be initiated.
If delisted, AgeX plans to have its common stock quoted on an electronic interdealer quotation system (OTC).
AgeX remains subject to conditions from prior deficiency letters regarding stockholders' equity.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Serina Therapeutics, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

Exchange: nyse american
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 1003(a)(i), 1003(a)(ii), 1003(a)(iii)

Exact text from the filing

April 20, 2023, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-013662

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.